Author: SA Transcript Insights Editor
Atea Pharma (AVIR) Q2 2026 earnings call: Phase III C-BEYOND HCV win vs Epclusa, C-FORWARD catalyst Q1’27, cash runway—read now.
Atea Pharma (AVIR) Q2 2026 earnings call: Phase III C-BEYOND HCV win vs Epclusa, C-FORWARD catalyst Q1’27, cash runway—read now.